Cargando…
Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012
KEYNOTE‐012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia‐Pacific region are reported. Patients with re...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834807/ https://www.ncbi.nlm.nih.gov/pubmed/29284202 http://dx.doi.org/10.1111/cas.13480 |
_version_ | 1783303710874533888 |
---|---|
author | Tahara, Makoto Muro, Kei Hasegawa, Yasuhisa Chung, Hyun Cheol Lin, Chia‐Chi Keam, Bhumsuk Takahashi, Kenichi Cheng, Jonathan D. Bang, Yung‐Jue |
author_facet | Tahara, Makoto Muro, Kei Hasegawa, Yasuhisa Chung, Hyun Cheol Lin, Chia‐Chi Keam, Bhumsuk Takahashi, Kenichi Cheng, Jonathan D. Bang, Yung‐Jue |
author_sort | Tahara, Makoto |
collection | PubMed |
description | KEYNOTE‐012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia‐Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (RECIST version 1.1), and ECOG performance status (PS) 0‐1 were eligible for enrollment in the HNSCC expansion cohort. Patients received pembrolizumab 200 mg every 3 weeks. Response was assessed every 8 weeks. Co‐primary end‐points were safety and overall response rate (RECIST version 1.1, central review). Secondary end‐points included overall survival and response duration. Patients enrolled at any of the five centers throughout the Asia‐Pacific region were included in these analyses. Twenty‐six patients with HNSCC from the Asia‐Pacific region received pembrolizumab. The median age was 62 years, 65% of patients had ECOG PS 1, and 62% had received two or more prior therapies for recurrent/metastatic disease. Sixteen (62%) patients experienced a treatment‐related adverse event of any grade, including two (8%) patients who experienced one or more events of grade 3 severity. No treatment‐related deaths occurred. The overall response rate was 19% (95% confidence interval, 7%‐39%). After a median follow‐up of 12 months (range, 2‐21 months), a median response duration was not reached (range, 6 to 17+ months); four of five responses lasted ≥6 months. Median overall survival was 11.6 months (95% confidence interval, 4.7‐17.7 months). Pembrolizumab was well tolerated and had durable antitumor activity in patients with HNSCC from the Asia‐Pacific region. (Trial registration no. NCT01848834.) |
format | Online Article Text |
id | pubmed-5834807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58348072018-03-06 Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 Tahara, Makoto Muro, Kei Hasegawa, Yasuhisa Chung, Hyun Cheol Lin, Chia‐Chi Keam, Bhumsuk Takahashi, Kenichi Cheng, Jonathan D. Bang, Yung‐Jue Cancer Sci Original Articles KEYNOTE‐012 was a phase Ib, multicohort study designed to investigate efficacy and safety of pembrolizumab in advanced solid tumors. Results from the subset of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) from the Asia‐Pacific region are reported. Patients with recurrent/metastatic HNSCC, measurable disease (RECIST version 1.1), and ECOG performance status (PS) 0‐1 were eligible for enrollment in the HNSCC expansion cohort. Patients received pembrolizumab 200 mg every 3 weeks. Response was assessed every 8 weeks. Co‐primary end‐points were safety and overall response rate (RECIST version 1.1, central review). Secondary end‐points included overall survival and response duration. Patients enrolled at any of the five centers throughout the Asia‐Pacific region were included in these analyses. Twenty‐six patients with HNSCC from the Asia‐Pacific region received pembrolizumab. The median age was 62 years, 65% of patients had ECOG PS 1, and 62% had received two or more prior therapies for recurrent/metastatic disease. Sixteen (62%) patients experienced a treatment‐related adverse event of any grade, including two (8%) patients who experienced one or more events of grade 3 severity. No treatment‐related deaths occurred. The overall response rate was 19% (95% confidence interval, 7%‐39%). After a median follow‐up of 12 months (range, 2‐21 months), a median response duration was not reached (range, 6 to 17+ months); four of five responses lasted ≥6 months. Median overall survival was 11.6 months (95% confidence interval, 4.7‐17.7 months). Pembrolizumab was well tolerated and had durable antitumor activity in patients with HNSCC from the Asia‐Pacific region. (Trial registration no. NCT01848834.) John Wiley and Sons Inc. 2018-02-08 2018-03 /pmc/articles/PMC5834807/ /pubmed/29284202 http://dx.doi.org/10.1111/cas.13480 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Tahara, Makoto Muro, Kei Hasegawa, Yasuhisa Chung, Hyun Cheol Lin, Chia‐Chi Keam, Bhumsuk Takahashi, Kenichi Cheng, Jonathan D. Bang, Yung‐Jue Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title | Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title_full | Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title_fullStr | Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title_full_unstemmed | Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title_short | Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 |
title_sort | pembrolizumab in asia‐pacific patients with advanced head and neck squamous cell carcinoma: analyses from keynote‐012 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834807/ https://www.ncbi.nlm.nih.gov/pubmed/29284202 http://dx.doi.org/10.1111/cas.13480 |
work_keys_str_mv | AT taharamakoto pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT murokei pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT hasegawayasuhisa pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT chunghyuncheol pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT linchiachi pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT keambhumsuk pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT takahashikenichi pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT chengjonathand pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 AT bangyungjue pembrolizumabinasiapacificpatientswithadvancedheadandnecksquamouscellcarcinomaanalysesfromkeynote012 |